AI-Designed Drug Candidates Show Clinical Progress Across US and Canadian Trials
Gene therapies, peptides, and antibodies developed with AI assistance are producing measurable safety and efficacy data in human trials across North America. Solid Biosciences' Duchenne muscular dystrophy treatment shows protein restoration in patients, while Canadian firm Arch Biopartners begins dosing trials for surgical kidney injury prevention. The programs demonstrate AI drug discovery translating computational predictions into clinical outcomes.
Salvado•